Rigid engagement models filter people out. Fixed schedules, limited locations, and one-way communication no longer fit the realities of many people’s lives: work patterns have shifted, caregiving responsibilities have grown, and digital access has improved unevenly across communities. Flexibility is no longer a bonus. It is a core requirement for meaningful engagement.
Flexible models pull people in and keep them there. Using flexible models to expand participation and retention allows studies to meet people where they are. When research adapts to real life rather than asking people to reshape their lives around a trial, more people can take part and more people stay involved until the end. This supports better data quality and more representative outcomes.
Many sponsors are already exploring new ways of working. Hybrid visits, remote check-ins, and varied communication channels are becoming more common, and attention often turns to structured frameworks such as the trialport patient engagement model for sponsors. These models help sponsors move beyond ad hoc flexibility and toward consistent, scalable approaches that support people and sites alike.
Flexibility also signals respect. When patients feel that their time, energy, and circumstances are valued, they are more likely to engage openly. This trust can make the difference between short-term participation and long-term commitment. It also supports more inclusive research by reducing barriers that have historically excluded many groups.
Using Flexible Models to Expand Participation and Retention
Participation begins with access. Flexible models widen the door by offering more ways to join a study. This might include remote consent, virtual screening, or local visit options. Each adjustment reduces friction. For people living far from research centers, or those with limited mobility, these changes can be decisive.
Retention depends on ongoing support. Flexible scheduling allows visits to fit around work or family life. Remote data collection can reduce travel fatigue. Clear communication channels help patients feel connected even when visits are less frequent. Together, these elements create a steadier experience that people can sustain over time.
Importantly, flexibility should be planned, not improvised. Clear protocols are needed so that sites understand what options are available and when they apply. Patients should receive consistent information, regardless of how they engage. This balance between adaptability and structure helps maintain study integrity while improving the patient experience.
Technology plays a role, but it is not the whole answer. Digital tools must be chosen with care, and alternatives should remain available. Not every patient has reliable internet access or feels confident using apps. True flexibility includes choice, not just innovation.
trialport Patient Engagement Model for Sponsors
Structured engagement models help sponsors operationalize flexibility. trialport’s contribution sits at the very start of the pathway: a plain-language summary with medifit™ + readifit™ self-reflection tools, where medifit asks “Is this trial right for my health?” and readifit asks “Is this trial right for my life?”. When people arrive at a site already understanding what participation involves, the flexibility offered downstream has something to build on.
Engagement strategies must be built into the study from the outset, rather than added later as fixes. This includes mapping patient journeys, identifying likely pressure points, and deciding where flexibility will have the greatest impact. For example, early feedback may highlight the need for varied visit times or additional support during treatment phases.
Sponsors benefit from this clarity. Sites receive guidance on how to offer flexibility without confusion. Patients receive consistent messaging about what to expect. Data collection remains robust because flexibility is designed within defined parameters. The result is a more predictable and patient-focused study environment.
Another strength of this approach is feedback. Ongoing input from patients helps refine engagement over time. This creates a learning loop that can improve current studies and inform future ones. Flexibility becomes a shared process rather than a one-sided offer.
Flexible Patient Engagement
Many engagement strategies center on flexible patient engagement as a driver of equity. When studies offer multiple ways to participate, they are more likely to reflect real-world populations. This is especially important for communities that have been underrepresented in research.
Flexible patient engagement can include varied communication styles, from phone calls to secure messaging. It can involve community-based support or partnerships with patient groups. Each option recognizes that engagement is not one-size-fits-all. What works for one group may not work for another.
Practical considerations remain important. Flexibility must comply with regulatory requirements and data protection standards. Clear documentation, training, and oversight are essential. Sponsors that adapt engagement pathways early see fewer downstream protocol deviations and fewer frustrated sites.
Looking ahead, flexibility is likely to become a standard expectation. People are increasingly aware of their choices and are more willing to engage with studies that respect their needs. Allowing people to engage on their terms improves retention more effectively than any reminder system ever will. Sponsors that invest in adaptable models now will be better positioned to meet these expectations and to keep more of the people they enroll.
Flexibility drives broader patient engagement by making research more humane and more realistic. It supports participation, improves retention, and builds trust over time. Sponsors who treat flexibility as an opportunity rather than a risk connect more deeply with the people their studies depend on. Stop asking people to fit research. Make research fit people. See what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, so that understanding a study comes before anyone is asked to join one. Understanding comes first. Decisions follow.